Security
Park Ha Biological Technology Co., Ltd. Class A Ordinary Shares · BYAH
BYAHNASDAQCommon stockCurrentCIK 1986247Updated Oct 6, 2026
BYAH price & chart
Loading TradingView…
NASDAQ:BYAH on TradingView ↗About the company
Technology Co., Ltd. Established in 2016, Park Ha Biological Technology Co., Ltd. is primarily engaged in developing its private skincare label, direct skincare product sales and franchise promotion under the proprietary brand “Park Ha”, with a commitment to providing cost-effective solutions to skin problems and improving the confidence of women in need of skin treatment. As of October 31, 2025, the Company has five directly operated stores and 22 franchisees in China. As part of its value-added service for the products, the Company offers “light beauty experience”, a quick complimentary after-sales beauty service performed in the directly operated stores and franchise stores. For more information, please visit the Company’s website: http://ir.parkha.cn/.
In the news
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Park Ha Biological Technology Co., Ltd. of Class Action Lawsuit and Upcoming Deadlines – BYAH ↗
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Park Ha Biological Technology Co., Ltd. of Class Action Lawsuit and Upcoming Deadlines – BYAH ↗
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Park Ha Biological Technology Co., Ltd. of Class Action Lawsuit and Upcoming Deadlines - BYAH ↗
Recent filings
6-K filing
6-K filing
SCHEDULE 13G - filed by Wang Li (Forest) regarding Park Ha Biological Technology Co., Ltd.
SCHEDULE 13G - filed by Meng Hao (Mike) regarding Park Ha Biological Technology Co., Ltd.
SCHEDULE 13G - filed by Ma Yajie regarding Park Ha Biological Technology Co., Ltd.
Show 5 more recent filings
SCHEDULE 13G - filed by Cao Jie (Jessie) regarding Park Ha Biological Technology Co., Ltd.
SCHEDULE 13G - filed by Xia Chunxin regarding Park Ha Biological Technology Co., Ltd.
SCHEDULE 13G - filed by Guo Yingying (Kathy) regarding Park Ha Biological Technology Co., Ltd.
SCHEDULE 13G - filed by Meng Qi (Maxi) regarding Park Ha Biological Technology Co., Ltd.
SCHEDULE 13G - filed by NG YEE LOON regarding Park Ha Biological Technology Co., Ltd.
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q2 2025 | Q2 2024 | FY 2025 | FY 2024 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 5,832,432Source | — | 5,952,616Source | 3,083,283Source |
| Property, Plant and Equipment, NetUSD | 88,967Source | — | 157,999Source | 103,960Source |
| Intangible Assets, Net (Excluding Goodwill)USD | 6,980Source | — | 6,639Source | 7,621Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | — | — | 3,787,678Source | 547,498Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 123,257Source | — | 255,844Source | 330,892Source |
| Inventory, NetUSD | 65,821Source | — | 75,214Source | 71,486Source |
| Assets, CurrentUSD | 5,584,630Source | — | 5,501,962Source | 2,844,246Source |
| Operating Lease, Right-of-Use AssetUSD | 91,198Source | — | 180,243Source | 70,739Source |
| Other Assets, NoncurrentUSD | 60,657Source | — | 105,773Source | 56,717Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 1,581,992Source | — | 1,957,761Source | 1,577,198Source |
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | 587Source | — | — | 500Source |
| Additional Paid in CapitalUSD | 1,161,211Source | — | — | 1,161,211Source |
| Retained Earnings (Accumulated Deficit)USD | -19,564,205Source | — | -24,178,267Source | 271,788Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -69,375Source | — | -66,400Source | -59,376Source |
| Stockholders' Equity Attributable to ParentUSD | 4,250,440Source | 1,068,008Source | 3,994,855Source | 1,506,085Source |
| Additional Paid in Capital, Common StockUSD | 23,751,471Source | — | 28,021,581Source | 1,161,211Source |
| Liabilities and EquityUSD | 5,832,432Source | — | 5,952,616Source | 3,083,283Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 1,518,932Source | — | 1,881,846Source | 1,524,453Source |
| Operating Lease, Liability, CurrentUSD | 28,402Source | — | 104,254Source | 17,573Source |
| Accounts Payable, CurrentUSD | 16,803Source | — | 12,013Source | 24,069Source |
| Operating Lease, Liability, NoncurrentUSD | 63,060Source | — | 75,915Source | 52,745Source |
cash flow · annual statements
| Line item | Q2 2025 | Q2 2024 | FY 2025 | FY 2024 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation and amortization | — | — | —Source | —Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | 24,070,200Source | — |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | -71,978Source | 98,740Source |
| Increase (Decrease) in InventoriesUSD | — | — | 17,458Source | -10,472Source |
| Increase (Decrease) in Accounts PayableUSD | — | — | -11,894Source | -176,130Source |
| Deferred Income Tax Expense (Benefit)USD | — | — | -26,671Source | -21,465Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | 85,852Source | 960,470Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | -572,927Source | -508,143Source |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | 3,735,677Source | -957,389Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 1,351,285Source | 931,966Source | 3,787,678Source | 547,498Source |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | -8,422Source | 18,926Source |
| Additional Financial Items | ||||
| Amortization of Intangible AssetsUSD | — | — | 970Source | 974Source |
| Deferred Other Tax Expense (Benefit)USD | — | — | -26,671Source | -21,465Source |
| DepreciationUSD | — | — | 108,399Source | 21,712Source |
| General and Administrative ExpenseUSD | — | — | 25,483,541Source | 814,857Source |
| Income Tax Expense (Benefit)USD | — | — | 280,646Source | 314,860Source |
| InterestExpenseNonoperatingUSD | — | — | 41Source | — |
| Inventory Write-downUSD | — | — | 1,430Source | 15,955Source |
| Investment Income, InterestUSD | — | — | 6,097Source | 783Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -24,364,753Source | 478,561Source |
| Nonoperating Income (Expense)USD | — | — | 64,794Source | -293Source |
| Operating ExpensesUSD | — | — | 26,531,218Source | 1,392,801Source |
| Operating Lease, ExpenseUSD | — | — | 37,386Source | 30,425Source |
| Other Nonoperating Income (Expense)USD | — | — | 58,738Source | — |
| Proceeds from Contributed CapitalUSD | — | — | — | 500Source |
| Proceeds from Issuance of Common StockUSD | — | — | 4,277,807Source | — |
| Financing Receivable, Credit Loss, Expense (Reversal)USD | — | — | 183,501Source | -8,580Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 |
|---|---|---|
| Total RevenueUSD | 2,524,843Source | 2,381,851Source |
| Cost of Goods and Services Sold | —Source | —Source |
| Operating Income (Loss)USD | -24,148,901Source | 793,714Source |
| Other Nonoperating Income (Expense)USD | 58,738Source | — |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -24,084,107Source | 793,421Source |
| Income Tax Expense (Benefit)USD | 280,646Source | 314,860Source |
| Net Income (Loss) Attributable to ParentUSD | -24,364,753Source | 478,561Source |
| Earnings Per Share, BasicUSD per share | -41.38Source | 0.02Source |
| Earnings Per Share, DilutedUSD per share | -41.38Source | 0.02Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 588,866Source | 25,000,000Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 588,866Source | 25,000,000Source |
| Interest Expense (non-operating)USD | 41Source | — |
| Additional Financial Items | ||
| Amortization of Intangible AssetsUSD | 970Source | 974Source |
| Current Income Tax Expense (Benefit)USD | 307,317Source | 336,325Source |
| Depreciation, Depletion and Amortization, NonproductionUSD | 109,369Source | 22,686Source |
| General and Administrative ExpenseUSD | 25,483,541Source | 814,857Source |
| Gross ProfitUSD | 2,382,317Source | 2,186,515Source |
| Investment Income, InterestUSD | 6,097Source | 783Source |
| Nonoperating Income (Expense)USD | 64,794Source | -293Source |
| Operating ExpensesUSD | 26,531,218Source | 1,392,801Source |
| Operating Lease, ExpenseUSD | 37,386Source | 30,425Source |
| Research and Development ExpenseUSD | 238,184Source | 36,714Source |
| Selling and Marketing ExpenseUSD | 625,289Source | 361,327Source |
Offerings
Registration 333-295090
Registration 333-290410
- Gross proceeds
- 2450000.0
- Net proceeds
- 2278500.0
- Deal price
- 0.112
- Shares
- 21875000
- Offering price
- $0.112
- Ticker
- BYAH
Filing attachments
ex4-1.htm · 6-K · 2026-09-11
Exhibit 4.1 CLASS A ORDINARY SHARE PURCHASE WARRANT Park Ha Biological Technology Co., Ltd. Warrant Issue Shares: _______ Date: ________________ Initial Exercise Date: ________________ THIS CLASS A ORDINARY SHARE PURCHASE WARRANT (the “ Warrant ”) certifies that, for value received, ____________ or its assigns (the “ Holder ”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinaft…
Read attachment ↗ea030019101ex4-1.htm · 6-K · 2026-08-03
Exhibit 4.1 CLASS A ORDINARY SHARE PURCHASE WARRANT Park Ha Biological Technology Co., Ltd. Warrant Shares: _______ Issue Date: ________________ Initial Exercise Date: ________________ THIS CLASS A ORDINARY SHARE PURCHASE WARRANT (the “Warrant”) certifies that, for value received, ____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or af…
Read attachment ↗ea029900901ex99-1.htm · 6-K · 2026-07-24
Exhibit 99.1 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our consolidated financial statements and related notes that appear in this report. In addition to historical consolidated financial information, the following discussion contains forward-looking statements that reflect our plans, estimates, and beliefs. Our actual result…
Read attachment ↗ea029900901ex99-2.htm · 6-K · 2026-07-24
Exhibit 99.2 Park Ha Biological Technology Co., Ltd. and its Subsidiaries Unaudited Interim Condensed Consolidated Balance Sheets As of April 30, 2026 and October 31, 2025 April 30, October 31, …
Read attachment ↗ea029780101ex99-1.htm · 6-K · 2026-07-13
Exhibit 99.1 THE COMPANIES ACT (REVISED) OF THE CAYMAN ISLANDS AMENDED AND RESTATED MEMORANDUM OF ASSOCIATION OF PARK HA BIOLOGICAL TECHNOLOGY CO., LTD. (ADOPTED PURSUANT TO SPECIAL SHAREHOLDER RESOLUTIONS DATED 13 JULY 2026) An Exempted Company Limited By Shares 1 NAME The name of the Company is Park Ha Biological Technology Co., Ltd. 2 STATUS The Company is a company limited by shares. 3 REGISTERED OFFICE The registered office of the Company is …
Read attachment ↗ea029716401ex99-1.htm · 6-K · 2026-07-06
Exhibit 99.1 Park Ha Biological Technology Co., Ltd. Announces Official Approval of Its North American Amazon Store, Launching a New Era of Brand Globalization Wuxi, China, July 06, 2026 (GLOBE NEWSWIRE) --Park Ha Biological Technology Co., Ltd. (NASDAQ: BYAH) (“Park Ha Biological” or the “Company”) announced that it has successfully passed the comprehensive and rigorous process to open a store on Amazon North America, and the cross-border store has been officially approved for opening and all…
Read attachment ↗